Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02039765 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetics and Safety of Topical Administration of Brimonidine Tartrate Ophthalmic Solution 0.025%.
A Phase 1 study, sponsored by Bausch & Lomb Incorporated.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT02039765 is a Phase 1 study that has completed, run by Bausch & Lomb Incorporated. The registered enrollment target is 12 participants.
The verdict
NCT02039765, a Phase 1 study, has completed, sponsored by Bausch & Lomb Incorporated.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
To characterize the plasma pharmacokinetics and safety profile of brimonidine following a single dose and 4 times per day (QID) dosing of brimonidine tartrate ophthalmic solution 0.025% for 7 days in healthy, adult subjects.
Interventions
- DRUG Brimonidine tartrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2014-02 |
| Est. Completion | 2014-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02039765
The ClinicalTrials.gov registry entry for NCT02039765 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bausch & Lomb Incorporated, which has 174 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Brimonidine tartrate is the first listed.
NCT02039765 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02039765 about?
NCT02039765 is a clinical study titled "Pharmacokinetics and Safety of Topical Administration of Brimonidine Tartrate Ophthalmic Solution 0.025%.". To characterize the plasma pharmacokinetics and safety profile of brimonidine following a single dose and 4 times per day (QID) dosing of brimonidine tartrate ophthalmic solution 0.025% for 7 days in healthy, adult subjects.
What is the current status of trial NCT02039765?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2014-02. Estimated completion is 2014-04.
What interventions are being tested in trial NCT02039765?
The interventions under investigation include: Brimonidine tartrate (DRUG).
Who is sponsoring clinical trial NCT02039765?
This trial is sponsored by Bausch & Lomb Incorporated, which has 174 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.